Cecilia Jones Sells 2,542 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) CFO Cecilia Jones sold 2,542 shares of the stock in a transaction dated Thursday, September 26th. The stock was sold at an average price of $49.03, for a total transaction of $124,634.26. Following the transaction, the chief financial officer now directly owns 20,158 shares in the company, valued at approximately $988,346.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Agios Pharmaceuticals Trading Down 4.4 %

AGIO opened at $42.47 on Wednesday. The business’s 50 day moving average is $45.47 and its 200-day moving average is $40.01. The stock has a market cap of $2.41 billion, a PE ratio of -6.72 and a beta of 0.75. Agios Pharmaceuticals, Inc. has a twelve month low of $19.80 and a twelve month high of $53.28.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings results on Thursday, August 1st. The biopharmaceutical company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.60) by ($0.09). The business had revenue of $8.60 million for the quarter, compared to the consensus estimate of $9.34 million. Agios Pharmaceuticals had a negative net margin of 1,165.69% and a negative return on equity of 47.05%. The business’s quarterly revenue was up 28.4% on a year-over-year basis. During the same period last year, the firm posted ($1.51) EPS. As a group, analysts forecast that Agios Pharmaceuticals, Inc. will post -4.85 EPS for the current year.

Institutional Investors Weigh In On Agios Pharmaceuticals

A number of hedge funds have recently made changes to their positions in AGIO. Acadian Asset Management LLC bought a new stake in shares of Agios Pharmaceuticals during the second quarter valued at approximately $37,000. Quest Partners LLC acquired a new position in shares of Agios Pharmaceuticals during the second quarter valued at approximately $40,000. NEOS Investment Management LLC acquired a new position in shares of Agios Pharmaceuticals during the fourth quarter valued at approximately $210,000. North Star Asset Management Inc. acquired a new position in shares of Agios Pharmaceuticals during the second quarter valued at approximately $216,000. Finally, XTX Topco Ltd acquired a new position in shares of Agios Pharmaceuticals during the second quarter valued at approximately $230,000.

Analyst Upgrades and Downgrades

AGIO has been the topic of several research analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and set a $55.00 price target on shares of Agios Pharmaceuticals in a research report on Thursday, September 19th. StockNews.com cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, August 5th. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $46.00 target price on shares of Agios Pharmaceuticals in a report on Thursday, June 13th. The Goldman Sachs Group raised their target price on shares of Agios Pharmaceuticals from $33.00 to $53.00 and gave the stock a “neutral” rating in a report on Tuesday, June 4th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Agios Pharmaceuticals in a report on Friday, September 20th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Agios Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $52.50.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.